Introduction Dupilumab is a treatment option newly licensed for adolescents with moderate
to severe atopic dermatitis (AD). It reduces type 2 inflammation by blocking the shared …

Objective Provide a review of atopic dermatitis management, focusing on optimizing topical
therapy, creating a stepwise approach for treatment plans, and providing guidance on when …

Background: Dupilumab, a monoclonal antibody inhibiting the signaling pathway of IL-4/IL-
13, was shown to be safe and effective in the treatment of moderate/severe atopic dermatitis …

Background: Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that
manifests in skin dryness, severe itching, and eczema, and can significantly impact a …

Atopic dermatitis (AD) is a highly heterogeneous disorder that has been assumed to be the
port of entry for IgE sensitization during early infancy and the first step in the atopic march …

Atopic dermatitis (AD) is a chronic inflammatory skin disease with pruritus, characterized by
recurrent eczema with exacerbations and remissions. AD impairs patients' QOL and places …

Atopic dermatitis (AD) is a common inflammatory skin disorder characterized by recurrent
eczematous lesions and intense itching. The disorder affects people of all ages and …

Background Dupilumab [a monoclonal antibody blocking the shared receptor subunit for
interleukin (IL)‐4 and IL‐13] is approved for patients aged≥ 12 years with inadequately …

Introduction: Atopic dermatitis is a common inflammatory skin disease with an increasing
prevalence. Treatment of patients suffering from mild or moderate disease includes the use …

Objective To discuss the efficacy and safety of novel and emerging topical and systemic
therapeutic agents for atopic dermatitis (AD). Data Sources The review of the published …